Financial PerformanceThermo Fisher Scientific reported a strong second quarter and updated its full-year 2025 guidance, raising expectations for both sales and adjusted earnings per share.
Investment StrategyTMO announced a US$2bn investment plan in the US, including US$1.5bn in Capex, to capture growing opportunities in reshoring manufacturing.
Market PositionThe synergies created by Thermo’s best-in-class service offerings have solidified its position as the partner of choice for the biopharma industry.